We schedule all diagnostic research and consultations for each patient on one day. Around 90% of all Dutch ALS patients are diagnosed in our centre and over 500 patients are diagnosed each year. Prof. Leonard van den Berg, director of the ALS Centre Netherlands, is one of the initiators of the TRICALS platform with the aim to speed up the research for an ALS treatment by increasing collaboration between patients, industry and ALS centres. He is also one of the initiators of Project Mine (www.projectmine.com), which is the largest research effort worldwide to study the genetic basis of ALS. Additionally, our research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.
Contact
Our team
Current trials
PHOENIX trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
ADORE trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
APL2-ALS-206 Trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
COURAGE-ALS Trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.